Kiyoshi Ariizumi, Ph.D. Titles and Appointments Professor School Medical School Department Dermatology Graduate Programs Cancer Biology, Immunology Biography We are interested in the mechanisms of a continuously changing equilibrium where the immune system tries to recognize and destroy cancer cells, while cancer cells accordingly acquire genetic alterations to evade immune surveillance. Our goals are to define molecular mechanisms through which cancers acquire resistance to immunotherapy; create new modalities to change the equilibrium towards immune dominance; and develop new approaches for functional precision cancer medicine. Education Graduate School University of Tokyo (1985) Research Interest Acquired resistance to immune checkpoint inhibitors Cancer-induced alterations of carbohydrate metabolism Functional precision cancer medicine Regulation of tumor angiogenesis Publications Featured Publications Acquired Resistance to Immune Checkpoint Therapy is Caused by Glycoprotein Non-Metastatic Melanoma Protein B Signal Cascade Chung JS, Ramani V, Guo L, Popat V, Cruz PD Jr., Xu L, Hammers H, Ariizumi K. Comms Med 2025 Accepted DC-HIL/Gpnmb is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors. Chung JS, Ramani V, Kobayashi M, Fattah FJ, Popat V, Zhang S, Cruz PD, Gerber DE, Ariizumi K, Clin. Cancer Res. 2019 Dec Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL/GPNMB antibody restores the in vitro integrity of T-cells from cancer patients. Kobayashi M, Chung JS, Beg M, Arriaga Y, Verma UN, Courtney K, Mansour JC, Haley B, Khan SA, Horiuchi Y, Ramani V, Harker D, Gopal P, Araghizadeh F, Cruz PD, Ariizumi K Clin. Cancer Res. 2018 Jul Myeloid-derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T cell-Suppressor Mechanisms. Cao LY, Chung JS, Teshima T, Feigenbaum L, Cruz PD, Jacobe HT, Chong BF, Ariizumi K J. Invest. Dermatol. 2016 May DC-HIL(+) CD14(+) HLA-DR(no/low) Cells Are a Potential Blood Marker and Therapeutic Target for Melanoma. Turrentine J, Chung JS, Nezafati K, Tamura K, Harker-Murray A, Huth J, Sharma RR, Harker DB, Ariizumi K, Cruz PD J. Invest. Dermatol. 2014 Jun DC-HIL is a negative regulator of T cell activation. Chung J-S, Sato K, Dougherty I, Cruz PD Jr, Ariizumi K. Blood Spring 2007 109 4320-4327 Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer. Hannan R, Dohopolski MJ, Pop LM, Mannala S, Watumull L, Mathews D, Gao A, Garant A, Arriaga YE, Bowman I, Chung JS, Wang J, Ariizumi K, Ahn C, Timmerman R, Courtney K, Biomedicines 2022 Jun 10 6 The DC-HIL/Syndecan-4 Pathway Regulates Autoimmune Responses through Myeloid-Derived Suppressor Cells. Chung JS, Tamura K, Akiyoshi H, Cruz PD, Ariizumi K J. Immunol. 2014 Feb Inhibition of T-cell activation by syndecan-4 is mediated by CD148 through protein tyrosine phosphatase activity. Chung JS, Cruz PD, Ariizumi K Eur. J. Immunol. 2011 Jun 41 6 1794-9 Sezary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Chung JS, Shiue LH, Duvic M, Pandya A, Cruz PD, Ariizumi K Blood 2011 Mar 117 12 3382-90 Results 1-10 of 16 1 2 Next Last Honors & Awards Research career Development AwardAwarded by the Dermatology Foundation (1994) Henry Christian Memorial AwardAwarded by the American Federation for Clinical Research (1993) Professional Associations/Affiliations American Association for Cancer Research (2015) Society of Investigative Dermatology (1994)
